The American Diabetes Association (ADA) has officially released its 2026 Standards of Medical Care in Diabetes, introducing several paradigm-shifting updates that directly impact clinical practice for endocrinologists, primary care physicians, and diabetes educators. The 400-page document, available online from June 1, 2026, emphasizes personalized glycemic goals, broader use of continuous glucose monitoring (CGM), and the first formal guidance on artificial intelligence (AI) decision support systems.
Key update #1: Time-in-Range (TIR) takes center stage. For most non-pregnant adults with type 1 or type 2 diabetes, the recommended TIR target (70–180 mg/dL) has been raised from >70% to >70% (unchanged numerically) but the new standards now define a “tight” control target of >75% for selected patients with high hypoglycemia resilience. More significantly, the guidelines introduce a secondary target of >50% for time in “tight range” (70–140 mg/dL) for patients using automated insulin delivery systems.
Key update #2: CGM is now recommended for all patients on intensive insulin regimens. Previous versions (2025) recommended CGM only for those with recurrent hypoglycemia or hypoglycemia unawareness. The 2026 update removes that restriction, stating: “Real-time CGM should be offered to all adults with type 1 diabetes and to those with type 2 diabetes on multiple daily injections or insulin pump therapy, regardless of hypoglycemia history.” This change is expected to add nearly 2 million new CGM users in the US alone.
Key update #3: AI-driven clinical decision support (CDS) is now recognized as an adjunctive tool. Section 7 (Diabetes Technology) includes a new subsection on “Intelligent Software Systems.” It states that AI-based platforms that analyze CGM data, food logs, and insulin doses to provide insulin dose recommendations “may be used at the discretion of the treating clinician, provided the algorithm has been validated in a peer-reviewed study.” The ADA stops short of full endorsement but explicitly warns against “autonomous dose adjustment without clinician oversight.”
Impact for SweetCare users: SweetCare’s AI-powered recommendation engine aligns with these new guidelines. The platform’s “Smart Insights” feature now includes a TIR tracker that flags when a patient falls below 70% over 14 days. We have also updated our clinical summary reports to highlight time-in-tight-range (70–140 mg/dL) per the new optional target.
What’s next? The ADA will host a live webinar on July 15, 2026, to discuss implementation. SweetCare will release a downloadable “2026 ADA Standards One-Pager” for clinicians later this month.